• Mashup Score: 7
    ASCO 2023 - Breast Cancer - 12 month(s) ago

    Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial El Saghir N Presentation # 1063 – PosterJune 4, 2023 | …

    Source: www.medicalcongresspresentations.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NagiSaghir
      NagiSaghir

      Proud to present RIGHT Choice trial subgroup analysis by age at #ASCO23 In Patients <40 with aggressive HR+ HER2- Advanced #breastcancer Cancer: #Ribociclib + ET (OFS + letrozole) PFS superior to combo chemo (HR 0.38) https://t.co/lAXQlfx5Yv @OncoAlert https://t.co/n3g38H1kzl